Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Study will no longer be conducted
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objective of the study is to optimize post-operative analgesia and improve patient satisfaction while reducing total opioid consumption after cesarean section
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| erector spinae plane block | Experimental | participants will be in this group for up to 9 months and receive erector spinae plane (ESP) block |
|
| standard of care | Experimental | participants in this group will receive the standard of care treatment and will be in this group for up to 9 months. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| erector spinae plane block (ESP) | Procedure | nerve block for abdominal pain. administered once immediately prior to spinal anesthetic standard of care. |
|
| Measure | Description | Time Frame |
|---|---|---|
| post-operative opioid analgesic medication | measurement (milligrams) | up to 24 hours |
| Measure | Description | Time Frame |
|---|---|---|
| change in post-operative pain medication by visual analog scale | Patient administered instrument to indicate pain on a level from 0 to10. (0: no pain. 10: worst imaginable pain) | baseline, up to 24 hours |
| number of minutes to first use of rescue medication |
Not provided
Inclusion criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Reine Zbeidy, MD | University of Miami | Principal Investigator |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010149 | Pain, Postoperative |
| ID | Term |
|---|---|
| D011183 | Postoperative Complications |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D010146 | Pain |
Not provided
Not provided
| ID | Term |
|---|---|
| D009020 | Morphine |
| D000077212 | Ropivacaine |
| D002045 | Bupivacaine |
| ID | Term |
|---|---|
| D009022 | Morphine Derivatives |
| D009019 | Morphinans |
| D053610 | Opiate Alkaloids |
| D000470 | Alkaloids |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Duramorph | Drug | 100 micrograms (mcg) of morphine administered in the spinal medications one time. |
|
| Ropivacaine | Drug | Ropivacaine 0.5% between 20-40 milliliters will be administered once in the ESP block (in the spine) depending on patient weight to keep under the maximum dose. |
|
| Bupivacaine Injection | Drug | Bupivacaine 0.75% 1.4-1.7 milliliters (10-12 milligrams) spinal medication. administered one time. |
|
the number of minutes calculated using the kaplan-meier. Calculated using the number of patients that did not need the rescue analgesic at the start of each day post-surgery, and the number of patients who needed the rescue analgesic. |
| up to 24 hours |
| obstetric quality of recovery scale | responses range from 0-10. zero is strongly agree, strongly disagree. | up to 24 hours |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D006571 |
| Heterocyclic Compounds |
| D006572 | Heterocyclic Compounds, Bridged-Ring |
| D006576 | Heterocyclic Compounds, 4 or More Rings |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D010616 | Phenanthrenes |
| D011084 | Polycyclic Aromatic Hydrocarbons |
| D011083 | Polycyclic Compounds |
| D000813 | Anilides |
| D000577 | Amides |
| D009930 | Organic Chemicals |
| D000814 | Aniline Compounds |
| D000588 | Amines |